select trial semaglutide results Full Affirm CV Risk Reduction With in Nondiabetics Long-term kidney outcomes of semaglutide – SELECT: Semaglutide's Impact on CVD

The FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide) specifically for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

Clarivate epidemiological forecasts forecast the total obese population in the country to exceed 500 million2 by 2033, suggesting a huge paradigm shift in the way the disease is currently dealt with

"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss." Diabetes, Obesity and Metabolism

Despite its benefits, semaglutide can cause side effects, including body aches

[DOI] [PMC free article] [PubMed] [Google Scholar] 12.Lushchak V.I., Lushchak O